Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
2.2000 x 1 2.2500 x 5
Post-market by (Cboe BZX)
2.2200 +0.3700 (+20.00%) 04/22/25 [NASDAQ]
2.2000 x 1 2.2500 x 5
Post-market 2.2200 unch (unch) 19:38 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.8900
Day High
2.2500
Open 1.8900
Previous Close 1.8500 1.8500
Volume 1,783,100 1,783,100
Avg Vol 2,526,750 2,526,750
Stochastic %K 80.08% 80.08%
Weighted Alpha -70.76 -70.76
5-Day Change +0.5200 (+30.59%) +0.5200 (+30.59%)
52-Week Range 1.3100 - 8.3300 1.3100 - 8.3300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,272
  • Shares Outstanding, K 70,958
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,790 K
  • EBIT $ -128 M
  • EBITDA $ -126 M
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.31

Options Overview Details

View History
  • Implied Volatility 131.55% ( -134.90%)
  • Historical Volatility 135.69%
  • IV Percentile 64%
  • IV Rank 15.29%
  • IV High 636.43% on 01/06/25
  • IV Low 40.45% on 06/11/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 384
  • Volume Avg (30-Day) 243
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 4,291
  • Open Int (30-Day) 4,765

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 6
  • High Estimate -0.39
  • Low Estimate -0.49
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +22.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +69.47%
on 03/26/25
Period Open: 1.5000
2.3400 -5.13%
on 03/27/25
+0.7200 (+48.00%)
since 03/21/25
3-Month
1.3100 +69.47%
on 03/26/25
Period Open: 2.4800
2.6100 -14.94%
on 01/24/25
-0.2600 (-10.48%)
since 01/22/25
52-Week
1.3100 +69.47%
on 03/26/25
Period Open: 7.3900
8.3300 -73.35%
on 05/03/24
-5.1700 (-69.96%)
since 04/22/24

Most Recent Stories

More News
Nkarta to Participate in an April Investor Conference

NKTX : 2.2200 (+20.00%)
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

NKTX : 2.2200 (+20.00%)
Nkarta to Participate in March Investor Conferences

NKTX : 2.2200 (+20.00%)
Nkarta, Inc. Opens Enrollment for Ntrust-2 Trial Evaluating NKX019 in Multiple Autoimmune Diseases

Nkarta opens Ntrust-2 trial for NKX019 in systemic sclerosis, myositis, and vasculitis; myasthenia gravis trial also initiated.Quiver AI SummaryNkarta, Inc. has announced the opening of patient enrollment...

NKTX : 2.2200 (+20.00%)
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

NKTX : 2.2200 (+20.00%)
Nkarta to Participate in an Upcoming Investor Conference

NKTX : 2.2200 (+20.00%)
Nkarta to Participate in an Upcoming Investor Conference

NKTX : 2.2200 (+20.00%)
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

NKTX : 2.2200 (+20.00%)
Why Nkarta Stock Is Soaring Today

One analyst is now more bullish about this clinical-stage biotech stock.

NKTX : 2.2200 (+20.00%)
RJF : 134.77 (+3.00%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.6000 (+4.35%)
NKTX : 2.2200 (+20.00%)
AMAM : 28.00 (+0.07%)
ELEV : 0.3720 (-1.61%)
ONC.TO : 0.84 (+6.33%)
AMGN : 278.40 (+1.72%)

Business Summary

Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 2.7100
2nd Resistance Point 2.4800
1st Resistance Point 2.3500
Last Price 2.2200
1st Support Level 1.9900
2nd Support Level 1.7600
3rd Support Level 1.6300

See More

52-Week High 8.3300
Fibonacci 61.8% 5.6500
Fibonacci 50% 4.8200
Fibonacci 38.2% 3.9900
Last Price 2.2200
52-Week Low 1.3100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro